Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation

References

• Bikiaris D, Karavelidis V, Karavas E. Effectiveness of various drug carriers in controlled release formulations of raloxifene HCl prepared by melt mixing. Curr Drug Deliv, 2009a;6(5):425–36
   PubMedGoogle Scholar
• Bikiaris D, Karavelidis V, Karavas E. Novel biodegradable polyesters: Synthesis and application as drug carriers for the preparation of raloxifene HCl loaded nanoparticles. Molecules, 2009b;14(7):2410–30
   PubMed Web of Science ®Google Scholar
• Burra M, Jukanti R, Janga K, Sunkavalli S, Velpula A, Ampati S, Jayaveera KN. Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. Adv Powder Technol, 2013;24:393–402
   Web of Science ®Google Scholar
• Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf, 2005;28(8):721–30
   PubMed Web of Science ®Google Scholar
• Comparisons of response surface designs [Online]. 2013. Available from: http://www.itl.nist.gov/div898/handbook/pri/section3/pri3363.htm. Accessed on 22 May 2013
   Google Scholar
• De Melo NF, De Araújo DR, Grillo R, Moraes CM, De Matos AP, de Paula E, Rosa AH, Fraceto LF. Benzocaine-loaded polymeric nanocapsules: Study of the anesthetic activities. J Pharm Sci, 2012;101(3):1157–65
   PubMed Web of Science ®Google Scholar
• De Melo NF, Grillo R, Guilherme VA, de Araujo DR, de Paula E, Rosa AH, Fraceto LF. Poly(lactide-co-glycolide) nanocapsules containing benzocaine: Influence of the composition of the oily nucleus on physicochemical properties and anesthetic activity. Pharm Res, 2011;28(8):1984–94
   PubMed Web of Science ®Google Scholar
• Deguchi T, Watanabe N, Kurihara A, Igeta K, Ikenaga H, Fusegawa K, Suzuki N, Murata S, Hirouchi M, Furuta Y, et al. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug Metab Dispos, 2011;39:820–9
   PubMed Web of Science ®Google Scholar
• Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv Drug Deliv Rev, 2012;64(6):557–70
   PubMed Web of Science ®Google Scholar
• Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: A critical evaluation of in-vivo studies. Crit Rev Ther Drug, 2005;22(5):419–64
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: Current state of development. Drug Aging, 2007;24(5):361–79
   PubMed Web of Science ®Google Scholar
• Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol, 1999;85:23–9
   PubMed Web of Science ®Google Scholar
• ICH stability testing of new drug substances and products [Online]. 2003. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002651.pdf. Accessed on 22 May 2013
   Google Scholar
• Kaleemuddin M, Srinivas P. Lyophilized oral sustained release polymeric nanoparticles of nateglinide. AAPS PharmSciTech, 2013;14(1):78–85
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurnya R, Doelkera E, Buria P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm, 1983;15(1):25–35
   Web of Science ®Google Scholar
• Lewis GA, Mathieu D, Phan-Tan-Luu R, eds. 1999. Pharmaceutical experimental design, 1st edn. New York: Marcel Dekker, Inc., pp. 39–40
   Google Scholar
• Mizuma T. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepaticglucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm, 2009;378(1–2):140–1
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: An integrated analysis and perspective. Annu Rev Pharmacol Toxicol, 2012;52:481–503
   PubMed Web of Science ®Google Scholar
• Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm, 2010;385(1–2):113–42
   PubMed Web of Science ®Google Scholar
• Negi LM, Jaggi M, Talegaonkar S. A logical approach to optimize the nanostructured lipid carrier system of irinotecan: Efficient hybrid design methodology. Nanotechnology, 2013;24(1):015104 . doi: 10.1088/0957-4484/24/1/015104
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev, 2001;47(1):55–64
   PubMed Web of Science ®Google Scholar
• Paul SD, Mazumder R, Bhattacharya S, Jha AK. Optimization of polymeric nano drug delivery system using 32 full factorial design. Curr Drug Deliv, 2013;10(4):394–403
   PubMed Web of Science ®Google Scholar
• Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv, 1985;60(4):110–11
   PubMedGoogle Scholar
• Peppas NA, Sahlin JJ. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm, 1989;57(2):169–72
   Web of Science ®Google Scholar
• Plapied L, Duhem N, Rieux A, Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci, 2011;16(3):228–37
   Web of Science ®Google Scholar
• Pohlmann AR, Fonseca FN, Paese K, Detoni CB, Coradini K, Beck RC, Guterres SS. Poly(-ε-caprolactone) microcapsules and nanocapsules in drug delivery. Expert Opin Drug Deliv, 2013;10(5):623–38
   PubMed Web of Science ®Google Scholar
• Rahman Z, Zidan AS, Habib MJ, Khan MA. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. Int J Pharm, 2010;389(1–2):186–94
   PubMed Web of Science ®Google Scholar
• Ravi P, Aditya N, Vats R. Development, validation and pharmacokinetic application of liquid chromatographic method for estimation of raloxifene hydrochloride in rabbit plasma. Acta Chromatogr, 2012;24(4):559–73
   Google Scholar
• Ravi PR, Aditya N, Kathuria H, Malekar S, Vats R. Lipid nanoparticles for oral delivery of raloxifene: Optimization, stability, in vivo evaluation and uptake mechanism. Eur J Pharm Biopharm, 2014. Available at: http://dx.doi.org/10.1016/j.ejpb.2013.12.015. Accessed on 27 Jan 2014
   Google Scholar
• Ravi PR, Vats R, Dalal V, Gadekar N, Aditya N. Design, optimization and evaluation of poly-ε-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir. Drug Dev Ind Pharm, 2013. [Epub ahead of print]. doi: 10.3109/03639045.2013.850710
   Google Scholar
• Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine, 2010;5(2):287–306
   PubMed Web of Science ®Google Scholar
• Singh S, Muthu MS. Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomedicine, 2007;2(2):233–40
   PubMed Web of Science ®Google Scholar
• Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-epsilon-caprolactone microspheres and nanospheres: An overview. Int J Pharm, 2004;278(1):1–23
   PubMed Web of Science ®Google Scholar
• Thakkar H, Nangesh J, Parmar M, Patel D. Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system. J Pharm Bioallied Sci, 2011;3:442–8
   PubMedGoogle Scholar
• Thörn H, Yasin M, Dickinson P, Lennernäs H. Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery. Xenobiotica, 2012;42:917–28
   PubMed Web of Science ®Google Scholar
• Tran T, Poudel B, Marasini N, Chi S, Choi H, Yong C, Kim JO. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent. Int J Pharm, 2013;443:50–7
   PubMed Web of Science ®Google Scholar
• Ubrich N, Bouillot P, Pellerin C, Hoffman M, Maincent P. Preparation and characterization of propranolol hydrochloride nanoparticles: A comparative study. J Control Release, 2004;97(2):291–300
   PubMed Web of Science ®Google Scholar
• Wempe MF, Wacher VJ, Ruble KM, Ramsey MG, Edgar KJ, Buchanan NL, Buchanan CM. Pharmacokinetics of raloxifene in male Wistar-Hannover rats: Influence of complexation with hydroxybutenyl-beta-cyclodextrin. Int J Pharm, 2008;346(1–2):25–37
   PubMed Web of Science ®Google Scholar
• Woodruff MA, Hutmacher DW. The return of a forgotten polymer—Polycaprolactone in the 21st century. Prog Polym Sci, 2010;35(10):1217–56
   Web of Science ®Google Scholar
• Yang YY, Chung TS, Ng NP. Morphology, drug distribution, and in-vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials, 2001;22(3):231–41
   PubMed Web of Science ®Google Scholar